Introduction
Thrombotic microangiopathies (TMAs) are a heterogeneous group of lifethreatening disorders characterized by thrombocytopenia, fragmentation of erythrocytes and ischemic organ damage which includes thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) [1] [2] [3] . TTP is often associated with a severe deficiency in the von Willebrand factor cleaving protease known as ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motifs, member 13). The deficiency can be due to autoantibodies (acquired TTP) 4, 5 or genetic mutations of ADAMTS13 (hereditary TTP) [6] [7] [8] .
Typical HUS is associated with and follows enterohemorrhagic E. coli infection with bloody diarrhea (D+ HUS), occurs mainly in children and is associated with acute renal failure 9, 10 . Atypical, diarrhea-negative (D-) HUS is very difficult to distinguish from TTP and has clearly overlapping clinical findings 1, 3, 11 . In D-HUS patients, several hereditary traits were recently identified that result in a hyperactivity of the alternative complement pathway, either by defective regulation of complement activation or by hyperfunctional mutations of complement factors 3, 11, 12 . Additional clinical conditions associated with TMAs are disseminated neoplasia, drugs including mitomycin C, quinine and ticlopidine, hematopoietic stem cell transplantation, pregnancy, certain autoimmune diseases and HIV infection [1] [2] [3] 13 .
Whereas almost all patients with hereditary TTP have severe constitutional ADAMTS13 deficiency and about 60% of patients clinically diagnosed with acquired TTP have severe autoantibody induced ADAMTS13 deficiency, it is well known that some patients with severe hereditary deficiency may remain asymptomatic for many years 6, 14 . Furthermore, some patients with acute TTP and severe acquired ADAMTS13
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From 4 deficiency go into clinical remission, but remain severely deficient in ADAMTS13 [15] [16] [17] suggesting a second hit is needed to bring about acute disease. Extracellular DNA and histones have recently been shown to contribute to thrombosis. Extracellular DNA fibers provide scaffolding for platelet adhesion and promote fibrin deposition 18, 19 . Extracellular DNA is part of thrombi in animals and contributes to thrombus formation and stability [18] [19] [20] . In vitro, histones induce platelet aggregation and enhance thrombin generation 21, 22 . When infused into mice, histones cause thrombocytopenia, promote thrombosis and contribute to organ damage and death 18, 20, [22] [23] [24] [25] .
Nucleosomes are a complex of DNA and histones and represent the basic building blocks of chromatin. Nucleosomes are released from necrotic tissue and are found in the circulation of patients with myocardical infarction, stroke, infections, trauma, cancer or autoimmune diseases 26 . Nucleosomes can also be liberated from inflammatory cells such as neutrophils. In response to infection or inflammatory stimuli, neutrophils release chromatin fibers, known as neutrophil extracellular traps (NETs) 27 . NETs bind microbes and contribute to host defense 27, 28 . NETs can also immobilize platelets and erythrocytes and stimulate thrombosis [18] [19] [20] . Histones and neutrophil proteases in NETs are in part responsible for the antimicrobial and prothrombotic functions [18] [19] [20] 27 . NETs are released from neutrophils after a cell death program, which proceeds from the dissolution of granular and nuclear membranes to chromatin decondensation and cytolysis 29 In addition, we quantified markers of inflammation, namely myeloperoxidase (MPO) from neutrophil granules 35 and S100A8/A9, a heterocomplex abundantly stored in neutrophil cytoplasm 36 . Our study reveals that nucleosomes and inflammatory markers are concomitantly elevated in acute TMA and reflect the disease state, also during periods of PEX. Inflammation in response to even a minor infection might result in the generation of extracellular DNA and histones and thus provide the trigger which brings about acute disease in patients at risk for TMA. 16, 38 and the FRETS-VWF73 assay 39 , slightly modified as previously described 40 . The detection limit of these assays is at 3-5%
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(immunoblotting) and 1% (FRETS-VWF73) of normal ADAMTS13 activity, respectively.
Quantification of nucleosomes
Nucleosomes were quantified by ELISA (Cell death detection kit, Roche) according to manufacturer's instructions. One unit of nucleosomes refers to the average amount of nucleosomes quantified in plasma from healthy controls.
Quantification of plasma DNA
Plasma was diluted in phosphate buffered saline (PBS, Gibco). Quantification of S100A8/S100A9 S100A8/A9 heterocomplexes (also known as Calprotectin) were quantified by ELISA (Human Calprotectin ELISA Kit, Hycultbiotech) according to manufacturer's instructions. One unit of S100A8/A9 refers to the average amount of S100A8/A9 quantified in plasma from healthy controls.
Quantification of MPO
MPO in plasma was quantified by means of a commercially available kit according to manufacturer's instructions (Zen MPO ELISA, Invitrogen). One unit of MPO refers to the average amount of MPO quantified in plasma from healthy controls.
Statistical evaluation
Statistical analysis was performed using Prism Software (GraphPad) and included MannWhitney test, Kruskal-Wallis test with Dunn's post hoc test and results were considered significant at P < 0.05. Spearman's rank correlation coefficients were calculated with Bonferroni-adjusted significance levels and considered significant at P < 0.005.
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From
Results
Acute TMAs are associated with increased levels of plasma DNA and nucleosomes.
We compiled a learning cohort of plasma samples from 29 patients with acute TMAs and 10 healthy controls (Supplemental Table 1 The length corresponds to DNA of mononucleosomes with residual linker DNA. Indeed, plasma nucleosomes are reported to be predominantly degraded to single units 26 . These findings also indicated that circulating DNA in TMA patients is predominantly of nuclear rather than mitochondrial origin. . We next quantified S100A8/A9 complexes in plasma. The complex belongs to a group of calcium binding S100 proteins and is expressed in different cell types, but mainly ascribed to circulating neutrophils and monocytes, in which it accounts for 50% of the cytosolic proteins 36 . S100A8/A9 is also known as myeloid-related protein 8/14 or calgranulin A/B, and is used as a diagnostic marker of inflammation in human plasma.
We measured S100A8/A9 in plasma by ELISA and detected elevated levels in . Our learning cohort included plasma samples from 5 patients with acquired TTP collected both at presentation with acute disease before any plasmatherapy and when the patients had achieved remission (Supplemental Table 1 ).
For (Figure 1 H, I ). This indicated that DNA, MPO and S100A8/A9 might reflect the disease activity in TTP patients, similar to LDH.
To test this idea, we compiled a second, investigational cohort with available plasma samples from 11 TTP patients collected at the day of admission, during therapy and in remission ( Table 1, Supplemental Table 2 ). First, we analyzed series of plasma samples collected during daily PEX and corticosteroid therapy of 5 patients with acute TTP due to a severe acquired ADAMTS13 deficiency (Table 1, Supplemental Table 2 , Patients A-E). We compared plasma DNA, MPO, ADAMTS13 activity and platelet counts during the disease course. Patients A (Figure 2 A, 3A) and B (Figure 2 B, 3B) represent examples of a good outcome during PEX and corticosteroid therapy. Patient A had at admission 35000 platelets/µl, 457 ng/ml DNA, 23.8-fold elevated levels of MPO and ADAMTS13 activity below 5% of normal with a circulating inhibitor (Supplemental Table 2 , Sample #45). Within 10 days of daily PEX, platelet counts recovered to 204000/µl, DNA levels reached 29 ng/ml, MPO levels became normal and ADAMTS13 activity was 100% (Supplemental Table 2 , # 45-54). Patient B was treated with three daily PEX after admission. Platelet counts increased from 29000 to 302000/µl at day 8.
DNA levels decreased from 729 ng/ml to 14 ng/ml. Plasma MPO at admission was 20.6-fold and at day 8 1.9-fold higher than in control samples. ADAMTS13 activity increased from less than 5% to 44% (Supplemental Table 2 , #60-63). Patient C (Figure 2 C, 3 C) did not achieve remission, progressively deteriorated and died during the course of
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therapy. The patient remained thrombocytopenic with platelet counts below 35000/µl throughout the 10 day disease course (Supplemental Table 2 , #65-76). At admission the DNA levels were approximately 4-fold higher than in control samples (132 ng/ml; Supplemental Table 2 , #65). During daily PEX and corticosteroid therapy, DNA levels progressively increased to extremely high levels and were approximately 530-fold higher compared to controls at day 10 (16404 ng/ml; Supplemental Table 2 Table 2 ). We analyzed plasma from Patient F obtained at the first acute episode, in remission and during two relapses (Supplemental Table 2 , #142-155). Plasma from Patient G was first obtained in remission 5 months after the second acute TTP episode (Supplemental Table 2 , #156-160). Thereafter, the patient relapsed three times and developed acute TTP episodes. Patient H was first seen in remission one year after the third acute episode and had one acute disease flare-up (Supplemental Table 2 We additionally analyzed plasma from three patients with hereditary TTP due to homozygous or compound heterozygous ADAMTS13 mutations, which lead to severe constitutional deficiency of ADAMTS13 activity (Patients I, J, K, Table 1; Supplemental   Table 2 , #164-171). Plasma DNA and MPO were elevated in acute disease bouts in 2 of 3 patients. In all remission samples of the 3 patients, DNA levels were normal but plasma MPO remained slightly elevated suggesting that clearance of circulating MPO could be altered in congenitally ADAMTS13 deficient patients. In summary, the data indicate that severe acquired and hereditary ADAMTS13 deficiency per se does not lead to an increase in extracellular DNA or MPO.
Next, we analyzed 100 samples from patients with acquired TTP from the investigational cohort of which ADAMTS13 activity, platelet counts, DNA as well as MPO levels were available (Supplemental Table 2 ). Consistent with our hypothesis, thrombocytopenia (platelet count < 50000/µl) was characterized by the combination of 
Discussion
Our results indicate that DNA/histone complexes are released during acute TMA and correlate with disease activity during therapy. DNA and histones stimulate thrombosis and cause cytotoxicity in mice 19, 20, 25 . It is conceivable that they are implicated in clinical characteristics such as thrombocytopenia, microthrombosis, organ damage and potentially mortality in patients with TMA.
Circulating DNA and histones in patients with TMA were fragmented. DNA is likely to be cleaved by endogenous DNase1 in plasma 42 . Activated protein C (APC) may be responsible for the cleavage of histones 25 Circulating DNA and histones in patients with TMA may originate from NETs.
We found that levels of S100A8/A9 and myeloperoxidase are strongly correlated with levels of plasma DNA in patients during acute disease. The triad of cytoplasmic, granular and nuclear components, which are released during NET formation in vitro 29, 47 and found in plasma during acute TMA, supports the idea that NETs or their degradation products, respectively, contribute to the pool of circulating DNA and histones. Interestingly, MPO can be liberated from activated neutrophils by degranulation only in moderate levels in vitro 47 and S100A8/A9 lacks transmembrane regions and it is not clear how the complex 36 . Cytolysis of neutrophils in the course of NET formation could provide a release mechanism 29, 47 and explain the high levels of MPO and S100A8/A9 in acute TMA. However, it is likely that plasma DNA originates also from other cell types 23, 26 , including tumor cells the in case of neoplasia-associated TMA.
Furthermore, DNA and histones may be liberated from necrotic tissue after ischemic damage. Under pathological conditions, extracellular DNA and histones may be part of a 
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